{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:30:12Z","timestamp":1790206212496,"version":"4.1.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0222229","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T13:25:27Z","timestamp":1568121927000},"page":"e0222229","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":46,"title":["Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-7367","authenticated-orcid":true,"given":"Mario","family":"Cruciani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio G.","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"issue":"9734","key":"pone.0222229.ref001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(10)60676-9","article-title":"Antiretroviral therapy and management of HIV infection","volume":"376","author":"PA Volberding","year":"2010","journal-title":"Lancet"},{"key":"pone.0222229.ref002","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"pone.0222229.ref003","first-page":"289","article-title":"Why are baseline HIV RNA levels 100,000 copies\/mL or greater associated with mortality after the initiation of antiretroviral therapy?","volume":"38","author":"E Wood","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"pone.0222229.ref004","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cid\/ciu221","article-title":"Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection","volume":"59","author":"DA Osterholzer","year":"2014","journal-title":"Clin Infect Dis"},{"key":"pone.0222229.ref005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/PPA.S65199","article-title":"Combination dolutegravir-abacavir-lamivudine in the management of HIV\/AIDS: clinical utility and patient considerations","volume":"9","author":"M Cruciani","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"pone.0222229.ref006","doi-asserted-by":"crossref","first-page":"e0155406","DOI":"10.1371\/journal.pone.0155406","article-title":"An Indirect Comparison of Efficacy and Safety of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Disoproxil Fumarate and Abacavir\/Lamivudine + Dolutegravir in Initial Therapy","volume":"11","author":"J M Llibre","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"pone.0222229.ref007","doi-asserted-by":"crossref","first-page":"e0162775","DOI":"10.1371\/journal.pone.0162775","article-title":"Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review","volume":"11","author":"GW Rutherford","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"pone.0222229.ref008","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"A Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"pone.0222229.ref009","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"32","author":"J Higgins","year":"2003","journal-title":"BMJ"},{"key":"pone.0222229.ref010","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2011"},{"key":"pone.0222229.ref011","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\"and why is it important to clinicians","volume":"336","author":"G Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"pone.0222229.ref012","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S2352-3018(17)30095-4","article-title":"ARIA study team. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study","volume":"4","author":"C Orrell","year":"2017","journal-title":"Lancet HIV"},{"issue":"9936","key":"pone.0222229.ref013","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"B Clotet","year":"2014","journal-title":"Lancet"},{"issue":"10107","key":"pone.0222229.ref014","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.","volume":"390","author":"J Gallant","year":"2017","journal-title":"Lancet"},{"issue":"10107","key":"pone.0222229.ref015","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"PE Sax","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"pone.0222229.ref016","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"SL Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0222229.ref017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial","volume":"12","author":"J van Lunzen","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"9868","key":"pone.0222229.ref018","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"SPRING-2 Study Group.Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"F Raffi","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"pone.0222229.ref019","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"JM Molina","year":"2015","journal-title":"Lancet HIV"},{"issue":"11","key":"pone.0222229.ref020","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","article-title":"SPRING-1 Team. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study","volume":"27","author":"HJ Stellbrink","year":"2013","journal-title":"AIDS"},{"issue":"11","key":"pone.0222229.ref021","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"F Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0222229.ref022","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Dolutegravir Plus Abacavir\/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial","volume":"70","author":"S Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"pone.0222229.ref023","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"HJ Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"issue":"6","key":"pone.0222229.ref024","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"DA Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"pone.0222229.ref025","unstructured":"EACS (European AIDS Clinical Society) Guidelines. Version 9.1. October 2018. Available at: http:\/\/www.eacsociety.org\/files\/2018_guidelines-9.1-english.pdf."},{"key":"pone.0222229.ref026","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3018(16)30016-9","article-title":"Integrase inhibitor versus protease inhibitor-based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study","volume":"3","author":"K Squires","year":"2016","journal-title":"Lancet HIV"},{"issue":"1","key":"pone.0222229.ref027","doi-asserted-by":"crossref","first-page":"e52562","DOI":"10.1371\/journal.pone.0052562","article-title":"Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis","volume":"8","author":"P Messiaen","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"pone.0222229.ref028","doi-asserted-by":"crossref","first-page":"e105653","DOI":"10.1371\/journal.pone.0105653","article-title":"48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis","volume":"9","author":"DA Patel","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"pone.0222229.ref029","doi-asserted-by":"crossref","first-page":"e0160087","DOI":"10.1371\/journal.pone.0160087","article-title":"Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials","volume":"11","author":"J You","journal-title":"PLoS One"},{"key":"pone.0222229.ref030","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"P Cahn","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"pone.0222229.ref031","doi-asserted-by":"crossref","first-page":"e0155406","DOI":"10.1371\/journal.pone.0155406","article-title":"An Indirect Comparison of Efficacy and Safety of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Disoproxil Fumarate and Abacavir\/Lamivudine + Dolutegravir in Initial Therapy","volume":"11","author":"J M Llibre","year":"2016","journal-title":"PLoS One."},{"issue":"6","key":"pone.0222229.ref032","doi-asserted-by":"crossref","first-page":"e65631","DOI":"10.1371\/journal.pone.0065631","article-title":"Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors","volume":"8","author":"J Weber","year":"2013","journal-title":"PLoS One."},{"issue":"10","key":"pone.0222229.ref033","doi-asserted-by":"crossref","first-page":"e77448","DOI":"10.1371\/journal.pone.0077448","article-title":"Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics","volume":"8","author":"F DeAnda","year":"2013","journal-title":"PLoS One"},{"key":"pone.0222229.ref034","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"JJ Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"pone.0222229.ref035","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile","volume":"60","author":"M Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0222229.ref036","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/infdis\/jiy186","article-title":"Resistance to Dolutegravir\u2014A Chink in the Armor?","volume":"218","author":"DR Kuritzkes","year":"2018","journal-title":"The Journal of Infectious Diseases"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0222229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T22:48:32Z","timestamp":1664318912000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0222229"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0222229","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]}}}